Literature DB >> 35176459

Added therapeutic benefit regarding ESMO-MCBS and the French health technology assessment of drugs granted early access program.

F Y-V Pham1, E Jacquet2, A Monard3, L Brunel4, J-Y Blay5, N Albin6.   

Abstract

Entities:  

Mesh：

Year:  2022        PMID： 35176459     DOI： 10.1016/j.annonc.2022.02.002

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  3 in total

Review 1.  Implications of Oncology Trial Design and Uncertainties in Efficacy-Safety Data on Health Technology Assessments.

Authors:  Dario Trapani; Kiu Tay-Teo; Megan E Tesch; Felipe Roitberg; Manju Sengar; Sara C Altuna; Michael J Hassett; Armando A Genazzani; Aaron S Kesselheim; Giuseppe Curigliano
Journal:  Curr Oncol       Date:  2022-08-16       Impact factor: 3.109

2.  Survival, cost and added therapeutic benefit of drugs granted early access through the French temporary authorization for use program in solid tumors from 2009 to 2019.

Authors:  Fiona Y-V Pham; Emmanuelle Jacquet; Amina Taleb; Adrien Monard; Ghania Kerouani-Lafaye; Florence Turcry; Liora Brunel; Françoise Grudé; Isabelle Yoldjian; Isabelle Sainte-Marie; Lotfi Boudali; Jean-Yves Blay; Nicolas Albin
Journal:  Int J Cancer       Date:  2022-07-07       Impact factor: 7.316

3.  Is It Time to Commit to a Process to Re-Evaluate Oncology Drugs? A Descriptive Analysis of Systemic Therapies for Solid Tumour Indications Reviewed in Canada from 2017 to 2021.

Authors:  Sandeep Sehdev; Alexandra Chambers
Journal:  Curr Oncol       Date:  2022-03-10       Impact factor: 3.677
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.